FluGen, Inc.

FluGen's M2SR in Lancet ID today showing superior resposne when combined with Fluzone High Dose in older adults versus Fluzone High Dose alone (thelancet.com/journals/lanin…) This could be a big improvement in preventing flu... bit.ly/3S3gvMC

And while you're at it- take a look at Healthcare Business Today to read more about M2SR's potential healthcarebusinesstoday.com/m2sr-vaccine-t…

Check us out in Drug Discovery & Development! drugdiscoverytrends.com/dual-defense-f…

On the latest episode of the @BioBossPodcast, FluGen Founder and CEO Paul Radspinner discusses his career journey and the science behind FluGen’s vaccine program. To hear the full podcast, head to the BioBoss website: bioboss.buzzsprout.com

We're excited to announce completion of first cohort in age de-escalation clinical trial of M2SR flu vaccine candidate in pediatric subjects ages 6 Months to 17 Years! flugen.com/news/

More confirmation that mucosal immunity is critical cnn.com/2022/07/18/hea…

.@UWMadison investigators are eligible to apply for @DeptofDefense funding to catalyze innovative medical solutions for military applications and rapidly migrate those technologies out of the lab and into use. #WisconsinInnovates engineering.wisc.edu/blog/with-10b-…

.@FluGenInc announced the dosing of its first subject, in an unprecedented study of older adults ages 65-85 years, to evaluate the effectiveness of its intranasal #flu #vaccine. ow.ly/hN7g50JJa8c #clinicaltrials

We are pleased to announce the first subject has been dosed in phase 1b clinical trial of our intranasal M2SR Flu Vaccine, co-administered with High Dose Vaccine, in older adults! See flugen.com/news/ for full announcement

[ALA Client News] #Naobios delivers @flugeninc’s M2SR #influenza #vaccine candidate for upcoming clinical trials @FluSpinner ala.com/projects/naobi…

FluGen to Present at 40th Annual J.P. Morgan Healthcare Conference 1/12/22 @ 4:30 PM E.T. Visit flugen.com/for-investors/ for more info!

FluGen management will be presenting at Baird's 2021 Global Healthcare Conference tonight @ 5:30 PM ET watch it here: kvgo.com/baird-2021-glo…

Journal of Infectious Diseases publishes positive data from our Ph.2 human challenge study of our M2SR #flu #vaccine candidate, showing protection against highly drifted strain of H3N2 flu [prn.to/3xeng0J]

We are happy to announce that @DeptofDefense has awarded us funding to conduct a safety & immunogenicity study to asses our M2SR #flu #vaccine candidate and the current standard of care high dose vaccine in adults 65 and older prn.to/2UbMcs2

Watch FluGen President & CEO Paul Radspinner speak at the @Jefferies 2021 Virtual Healthcare Conference wsw.com/webcast/jeff17…

We are pleased to launch the first #flu #vaccine study of M2SR in adults up to 85. Funded by @NIH, our study will assess safety, tolerability, and immunological response in people vulnerable to flu. prn.to/2TcY3Wd

How @UWMadisonURP started How it's going

ICYMI, watch my interview with @FluGenInc CEO Paul Radspinner. We chatted about FluGen’s approach to developing a Covid-19 vaccine, what the biggest challenges are, and what vaccine-makers need to do to ensure patients they are safe and effective. bizjournals.com/milwaukee/inno…

Reminder: you can still register for tomorrow's virtual fireside chat to hear from our CEO Paul Radspinner